Literature DB >> 35124564

Ginsenoside Rd attenuates cerebral ischemia/reperfusion injury by exerting an anti-pyroptotic effect via the miR-139-5p/FoxO1/Keap1/Nrf2 axis.

Yiqin Yao1, Sheng Hu1, Chunxue Zhang2, Qun Zhou3, Hui Wang2, Ya Yang1, Chao Liu4, Haiyan Ding5.   

Abstract

Pyroptosis mediated by nucleotide-binding oligomerization domain (NOD)-like receptor 3 (NLRP3) inflammasome is implicated in cerebral ischemia/reperfusion (I/R) injury. Ginsenoside Rd (Rd), a monomer component of Panax ginseng and Panax notoginseng, is reported to confer neuroprotection in brain injury models. However, the role of pyroptosis in Rd-mediated neuroprotection following cerebral I/R has not been investigated. We aimed to confirm the neuroprotective function and underlying mechanisms of Rd on pyroptosis after cerebral I/R using a middle cerebral artery occlusion/reperfusion (MCAO/R) model in male C57BL/6 mice, and oxygen-glucose deprivation/reoxygenation (OGD/R) model in primary cortical neurons. MicroRNA-139-5p (miR-139-5p) downregulation, forkhead box transcription factor O1 (FOXO1) and Kelch-like ECH-associated protein 1 (Keap1) upregulation, nuclear factor erythroid-2 related factor 2 (Nrf2) antioxidant pathway inactivation, reactive oxygen species (ROS)-driven thioredoxin-interacting protein (TXNIP) over-expression, and NLRP3 inflammasome activation-induced pyroptosis were observed in ischemic cortical tissues and primary neurons under MCAO/R and OGD/R induction. More importantly, Rd upregulated miR-139-5p to inhibit FoxO1 which regulates Keap1 transcriptional activity, and subsequently activates the Nrf2 antioxidant pathway, resulting in attenuation of ROS/TXNIP/NLRP3 inflammasome axis-driven pyroptosis in these animal and cell models. In summary, an anti-pyroptotic effect via the miR-139-5p/FoxO1/Keap1/Nrf2 axis may be the mechanism by which Rd attenuates ischemic stroke.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  Cerebral ischemia/reperfusion injury; Ginsenoside Rd; NLRP3 inflammasome; Pyroptosis; miR-139-5p

Mesh:

Substances:

Year:  2022        PMID: 35124564     DOI: 10.1016/j.intimp.2022.108582

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   5.714


  5 in total

Review 1.  Potential benefits of ginseng against COVID-19 by targeting inflammasomes.

Authors:  Young-Su Yi
Journal:  J Ginseng Res       Date:  2022-04-04       Impact factor: 5.735

2.  Interleukin-35 attenuates blood-brain barrier dysfunction caused by cerebral ischemia-reperfusion injury through inhibiting brain endothelial cell injury.

Authors:  Lei Qian; Ming Li; Xin Lin; Hongwei Teng; Lulu Yu; Maorong Jiang
Journal:  Ann Transl Med       Date:  2022-07

3.  Neuroprotective Effect and Possible Mechanisms of Ginsenoside-Rd for Cerebral Ischemia/Reperfusion Damage in Experimental Animal: A Meta-Analysis and Systematic Review.

Authors:  Ai-Fang Zhou; Ke Zhu; Pei-Min Pu; Zhuo-Yao Li; Ya-Yun Zhang; Bing Shu; Xue-Jun Cui; Min Yao; Yong-Jun Wang
Journal:  Oxid Med Cell Longev       Date:  2022-09-01       Impact factor: 7.310

Review 4.  A Review of Neuroprotective Effects and Mechanisms of Ginsenosides From Panax Ginseng in Treating Ischemic Stroke.

Authors:  Aimei Zhao; Nan Liu; Mingjiang Yao; Yehao Zhang; Zengyu Yao; Yujing Feng; Jianxun Liu; Guoping Zhou
Journal:  Front Pharmacol       Date:  2022-07-07       Impact factor: 5.988

Review 5.  Panax ginseng as a potential therapeutic for neurological disorders associated with COVID-19; Toward targeting inflammasome.

Authors:  Seo Won Shin; Ik Hun Cho
Journal:  J Ginseng Res       Date:  2022-10-04       Impact factor: 5.735

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.